Benzinga | Nov 4, 2021 06:32AM EDT

Regeneron Pharmaceuticals Q3 Adj. EPS $15.37 Beats $9.49 Estimate, Sales $3.45B Beat $2.79B Estimate

Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $15.37 per share which beat the analyst consensus estimate of $9.49 by 61.96 percent. This is a 83.85 percent increase over earnings of $8.36 per share from the same period last year. The company reported quarterly sales of $3.45 billion which beat the analyst consensus estimate of $2.79 billion by 23.76 percent. This is a 50.52 percent increase over sales of $2.29 billion the same period last year.